QURE
uniQure NV
NASDAQ · Healthcare · Biotechnology · NL
$21.78
−3.29%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$22.34
From 52W high−69.15%
Volume1.26M
Market cap$1.51B
P/E (TTM)—
P/S (TTM)80.9x
Div yield—
Key dataOct 16, 2026
Open
$22.34
From 52W high
−69.15%
Volume
1.26M
Market cap
$1.51B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.2x
P/E (TTM)
—
RSI (14)
23.0
MomentumView details →
1D Return
−3.29%
YTD Return
−8.29%
SummaryUpdated Jun 1, 2026
uniQure N.V. (NASDAQ:QURE) is a Dutch gene therapy company founded in 1998 and headquartered in Amsterdam, the Netherlands. The company went public on NASDAQ in February 2014. uniQure focuses on developing gene therapies for patients suffering from genetic and other devastating diseases, with a particular emphasis on rare neurological conditions and inherited disorders. The company has evolved from its early research phases to become a clinical-stage biotechnology firm with multiple programs advancing through various stages of human trials.
Similar companies
Latest newsMore news →
SueWallSt announced a pending investigation into potential securities law violations by uniQure following a decline in QURE shares after its four-year AMT-130 Huntington's disease data came in smaller than the three-year result.17d agoUniqure shares plummeted 40% on Tuesday after a disappointing four-year update for its experimental gene therapy in Huntington's disease patients.17d agouniQure announced additional data from ongoing Phase I/II studies of ifezuntirgene inilparvovec (AMT-130) in Huntington's disease, showing continued slowing of disease progression in 12 high-dose patients at 48 months.17d ago